

Acute Coronary Syndrome: Practical Application of Clinical Practice Guidelines and Recent Research Results to a Patient Case

References

1. American Heart Association. Heart disease and stroke statistics—2007 update. *Circulation*. 2007; 115:e69-e171.
2. Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. *J Manag Care Pharm*. 2005; 11:300-6.
3. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). *J Am Coll Cardiol*. 2002;40:1366-74.
4. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). *J Am Coll Cardiol*. 2004; 44:671-719.
5. CRUSADE National Quality Improvement Initiative. 2006 Crusade third quarter results.
<http://www.crusadeqi.com/Main/Ecab/Slides/CRUSADEResults2006Q3.ppt>
(accessed 2007 Mar 22).
6. Alexander KP, Chen AY, Roe MT et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. *JAMA*. 2005; 294:3108-16.
7. Alexander KP, Chen AY, Newby LK et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. *Circulation*. 2006; 114:1380-7.
8. Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA*. 2004; 292:45-54.
9. Collet JP, Montalescot G, Lison L et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. *Circulation*. 2001; 103:658-63.

Acute Coronary Syndrome: Practical Application of Clinical Practice Guidelines and Recent Research Results to a Patient Case

10. Olson JD, Arkin CF, Brandt JT et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. *Arch Pathol Lab Med.* 1998; 122:782-98.
11. Martin JL, Fry ET, Sanderink GJ et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. *Catheter Cardiovasc Interv.* 2004; 61:163-70.
12. Ferguson JJ, Antman EM, Bates ER et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. *Am Heart J.* 2003; 146:628-34.
13. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. *N Engl J Med.* 2006; 355:2203-16.
14. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. *JAMA.* 2003; 289:853-63.
15. Rao AK, Pratt C, Berke A et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. *J Am Coll Cardiol.* 1988; 11:1-11.
16. Yusuf S, Mehta SR, Chrolavicius S et al for the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med.* 2006; 354:1464-76.
17. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. *N Engl J Med.* 1994; 330:956-61.
18. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. *N Engl J Med.* 1997; 336:1689-96.
19. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med.* 2005; 352:1179-89.
20. Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet.* 2005; 366:1607-21.

Acute Coronary Syndrome: Practical Application of Clinical Practice Guidelines and Recent Research Results to a Patient Case

21. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. *N Engl J Med.* 2006; 354:1477-88.
22. Yusuf S, Mehta SR, Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. *JAMA.* 2006; 295:1519-30.